<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Prevtec Microbia</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:f19df3e4-4fbe-4666-9a5e-ee66dfd5a088;id=38821</id> <rights type="text">Copyright 2019, Prevtec Microbia</rights> <updated>2019-08-01T10:34:14Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/0I7aCIurthPe1lq32xJqfA==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/0I7aCIurthPe1lq32xJqfA==" /> <entry> <id>https://www.globenewswire.com/news-release/2019/08/01/1895386/0/en/Prevtec-Microbia-to-be-Acquired-by-Elanco.html</id> <title type="text">Prevtec Microbia to be Acquired by Elanco</title> <published>2019-08-01T10:34:14Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/08/01/1895386/0/en/Prevtec-Microbia-to-be-Acquired-by-Elanco.html" /> <content type="html"><![CDATA[Deal supports development of Prevtec Microbia’s pipeline and product expansion <pre>Deal supports development of Prevtec Microbia’s pipeline and product expansion</pre>]]></content> <dc:identifier>1895386</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia</dc:contributor> <dc:modified>Thu, 01 Aug 2019 10:33 GMT</dc:modified> <dc:subject>Mergers and Acquisitions</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/08/01/1895386/0/fr/Prevtec-Microbia-est-acquise-par-Elanco.html</id> <title type="text">Prevtec Microbia est acquise par Elanco</title> <published>2019-08-01T10:34:14Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/08/01/1895386/0/fr/Prevtec-Microbia-est-acquise-par-Elanco.html" /> <content type="html"><![CDATA[L’entente supporte le développement de son portefeuille et l’expansion de ses produits <pre>L’entente supporte le développement de son portefeuille et l’expansion de ses produits</pre>]]></content> <dc:identifier>1895386</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia</dc:contributor> <dc:modified>Thu, 01 Aug 2019 10:33 GMT</dc:modified> <dc:subject>Mergers and Acquisitions</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/10/18/1623590/0/en/The-Meritorious-Service-Medal-Awarded-to-Doctor-%C3%89ric-Nadeau-and-Doctor-John-Morris-Fairbrother.html</id> <title type="text">The Meritorious Service Medal Awarded to Doctor Éric Nadeau and Doctor John Morris Fairbrother</title> <published>2018-10-18T15:25:28Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/10/18/1623590/0/en/The-Meritorious-Service-Medal-Awarded-to-Doctor-%C3%89ric-Nadeau-and-Doctor-John-Morris-Fairbrother.html" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, Oct. 18, 2018 (GLOBE NEWSWIRE) -- <strong>Prevtec Microbia Inc. (Prevtec)</strong> - Dr. Éric Nadeau, co-founder and Vice-President, Scientific Affairs at Prevtec Microbia and adjunct professor at the Faculté de médecine vétérinaire of the Université de Montréal and Dr. John Morris Fairbrother, also co-founder of Prevtec Microbia and professor at the Faculté de médecine vétérinaire of the Université de Montréal, will receive the Meritorious Service Medal from the Governor General of Canada, Her Excellency the Right Honorable Julie Payette, in recognition of their work that led to the invention of Coliprotec®, innovative vaccines that are alternatives to antibiotics in pig production, and that led to the foundation of Prevtec Microbia Inc.<br></p>]]></content> <dc:identifier>1623590</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia</dc:contributor> <dc:modified>Thu, 18 Oct 2018 15:25 GMT</dc:modified> <media:content medium="image" type="image/png" width="600" url="https://resource.globenewswire.com/Resource/Download/99b67687-ddd9-4833-bbc3-be83e156f2eb"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2018/10/18/1623590/0/en/The-Meritorious-Service-Medal-Awarded-to-Doctor-%C3%89ric-Nadeau-and-Doctor-John-Morris-Fairbrother.html"> <img src="https://resource.globenewswire.com/Resource/Download/99b67687-ddd9-4833-bbc3-be83e156f2eb" width="600" align="left" border="0" alt="The Meritorious Service Medal Awarded to Doctor Éric Nadeau and Doctor John Morris Fairbrother" title="Dr. John Morris Fairbrother (left) and Dr. Éric Nadeau (right)" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/10/18/1623590/0/fr/La-M%C3%A9daille-du-Service-M%C3%A9ritoire-d%C3%A9cern%C3%A9e-aux-docteurs-%C3%89ric-Nadeau-et-John-Morris-Fairbrother.html</id> <title type="text">La Médaille du Service Méritoire décernée aux docteurs Éric Nadeau et John Morris Fairbrother</title> <published>2018-10-18T15:25:28Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/10/18/1623590/0/fr/La-M%C3%A9daille-du-Service-M%C3%A9ritoire-d%C3%A9cern%C3%A9e-aux-docteurs-%C3%89ric-Nadeau-et-John-Morris-Fairbrother.html" /> <content type="html"><![CDATA[<p align="justify">MONTRÉAL, 18 oct. 2018 (GLOBE NEWSWIRE) -- <strong>Prevtec Microbia inc. (« Prevtec »)</strong> - Le docteur Éric Nadeau, cofondateur et Vice-Président aux affaires scientifiques de Prevtec Microbia et professeur associé à la Faculté de médecine vétérinaire de l’Université de Montréal et le docteur John Morris Fairbrother, aussi cofondateur de Prevtec Microbia et professeur titulaire de la faculté de médecine vétérinaire de l’Université de Montréal recevront sous peu la Médaille du Service Méritoire de la Gouverneure générale du Canada, son Excellence la très honorable Julie Payette, en reconnaissance de leurs travaux qui ont mené à l’invention des produits vétérinaires Coliprotec®, des vaccins innovants alternatifs aux antibiotiques en production porcine et la création de l’entreprise Prevtec Microbia inc.<br></p>]]></content> <dc:identifier>1623590</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia</dc:contributor> <dc:modified>Thu, 18 Oct 2018 15:25 GMT</dc:modified> <media:content medium="image" type="image/png" width="600" url="https://resource.globenewswire.com/Resource/Download/99b67687-ddd9-4833-bbc3-be83e156f2eb"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2018/10/18/1623590/0/fr/La-M%C3%A9daille-du-Service-M%C3%A9ritoire-d%C3%A9cern%C3%A9e-aux-docteurs-%C3%89ric-Nadeau-et-John-Morris-Fairbrother.html"> <img src="https://resource.globenewswire.com/Resource/Download/99b67687-ddd9-4833-bbc3-be83e156f2eb" width="600" align="left" border="0" alt="La Médaille du Service Méritoire décernée aux docteurs Éric Nadeau et John Morris Fairbrother" title="Docteur John Morris Fairbrother (à gauche) et Docteur Éric Nadeau (à droite)" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/05/03/1495856/0/en/Five-million-doses-of-Prevtec-Microbia-s-bivalent-vaccine-Coliprotec-F4-F18-Sold-in-the-European-Union.html</id> <title type="text">Five million doses of Prevtec Microbia’s bivalent vaccine Coliprotec® F4/F18 Sold in the European Union</title> <published>2018-05-03T12:00:00Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/05/03/1495856/0/en/Five-million-doses-of-Prevtec-Microbia-s-bivalent-vaccine-Coliprotec-F4-F18-Sold-in-the-European-Union.html" /> <content type="html"><![CDATA[<p align="justify">MONTREAL, May 03, 2018 (GLOBE NEWSWIRE) -- Prevtec Microbia Inc. (“Prevtec”) is pleased to announce that five million doses of its bivalent vaccine Coliprotec® F4/F18 have been sold in the European Union (EU) since its commercial market authorization in 2017.<br></p>]]></content> <dc:identifier>1495856</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia</dc:contributor> <dc:modified>Thu, 03 May 2018 12:04 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>Coliprotec</dc:keyword> <dc:keyword>Bivalent vaccine</dc:keyword> <dc:keyword>swine</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/05/03/1495856/0/fr/Prevtec-Microbia-atteint-le-seuil-de-cinq-millions-de-doses-vendues-en-Union-Europ%C3%A9enne-pour-son-vaccin-bivalent-Coliprotec-F4-F18.html</id> <title type="text">Prevtec Microbia atteint le seuil de cinq millions de doses vendues en Union Européenne pour son vaccin bivalent Coliprotec® F4/F18</title> <published>2018-05-03T12:00:00Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/05/03/1495856/0/fr/Prevtec-Microbia-atteint-le-seuil-de-cinq-millions-de-doses-vendues-en-Union-Europ%C3%A9enne-pour-son-vaccin-bivalent-Coliprotec-F4-F18.html" /> <content type="html"><![CDATA[<p align="justify">MONTRÉAL, 03 mai 2018 (GLOBE NEWSWIRE) -- Prevtec Microbia Inc. (« Prevtec ») a le plaisir d’annoncer que son vaccin bivalent Coliprotec® F4/F18 a atteint le seuil de cinq millions de doses vendues en Union Européenne (UE) depuis l’obtention de l’autorisation de mise en marché sur ce territoire en 2017.<br></p>]]></content> <dc:identifier>1495856</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia</dc:contributor> <dc:modified>Thu, 03 May 2018 12:04 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>Coliprotec</dc:keyword> <dc:keyword>Bivalent vaccine</dc:keyword> <dc:keyword>swine</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/01/15/1324407/0/fr/Prevtec-Microbia-re%C3%A7oit-une-autorisation-de-mise-en-march%C3%A9-du-Coliprotec-F4-de-la-part-du-USDA.html</id> <title type="text">Prevtec Microbia reçoit une autorisation de mise en marché du Coliprotec® F4 de la part du USDA</title> <published>2018-01-15T15:15:28Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/01/15/1324407/0/fr/Prevtec-Microbia-re%C3%A7oit-une-autorisation-de-mise-en-march%C3%A9-du-Coliprotec-F4-de-la-part-du-USDA.html" /> <content type="html"><![CDATA[<p><em><p>Un financement d'un important fonds d'investissement canadien jusqu'à hauteur de CAD$10 millions est obtenu</p></em></p><p><strong>MONTRÉAL, QUÉBEC--(Marketwired - 15 jan. 2018) -</strong> Prevtec Microbia Inc. (« Prevtec ») a le plaisir d'annoncer qu'elle a reçu l'autorisation de commercialiser le vaccin Coliprotec® F4 de la part du Centre des produits biologiques vétérinaires du département de l'Agriculture des États-Unis (USDA-CVB). Le Coliprotec® F4 est un produit de première ligne indiqué pour l'immunisation des porcelets contre la diarrhée post-sevrage (DPS).</p>]]></content> <dc:identifier>1324407</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/01/15/1324405/0/en/Prevtec-Microbia-Receives-Market-Authorization-from-USDA-for-Coliprotec-F4.html</id> <title type="text">Prevtec Microbia Receives Market Authorization from USDA for Coliprotec® F4</title> <published>2018-01-15T15:14:18Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/01/15/1324405/0/en/Prevtec-Microbia-Receives-Market-Authorization-from-USDA-for-Coliprotec-F4.html" /> <content type="html"><![CDATA[<p><em><p>Up to CAD$10 million in Financing Secured from a Large Canadian Investment Fund</p></em></p><p><strong>MONTREAL, QUEBEC--(Marketwired - Jan. 15, 2018) -</strong> Prevtec Microbia Inc. ("Prevtec") is pleased to announce that it has received a market authorization from the Centre for Veterinary Biologics U.S. of the Department of Agriculture (USDA-CVB) to commercialize its vaccine Coliprotec® F4 in the US, a front line product against post weaning diarrhea (PWD) in pigs. </p>]]></content> <dc:identifier>1324405</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/10/24/1324402/0/fr/Prevtec-Microbia-re%C3%A7oit-une-autorisation-de-mise-sur-le-march%C3%A9-du-Coliprotec-R-F4-F18-en-Russie-et-dans-les-pays-de-la-CEI.html</id> <title type="text">Prevtec Microbia reçoit une autorisation de mise sur le marché du Coliprotec(R) F4/F18 en Russie et dans les pays de la CEI</title> <published>2017-10-24T17:47:26Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/10/24/1324402/0/fr/Prevtec-Microbia-re%C3%A7oit-une-autorisation-de-mise-sur-le-march%C3%A9-du-Coliprotec-R-F4-F18-en-Russie-et-dans-les-pays-de-la-CEI.html" /> <content type="html"><![CDATA[<p><strong>MONTRÉAL, QUÉBEC--(Marketwired - 24 oct. 2017) -</strong> Prevtec Microbia Inc. (« Prevtec ») a le plaisir d'annoncer qu'elle a reçu l'autorisation de commercialiser le vaccin bivalent Coliprotec® F4/F18 en Russie, y compris dans les pays de la CEI. Ce produit de première ligne est indiqué pour l'immunisation des porcelets contre la diarrhée post-sevrage (DPS) causée par la bactérie <em>E. coli</em>.</p>]]></content> <dc:identifier>1324402</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/10/24/1324399/0/en/Prevtec-Microbia-Receives-Market-Authorization-for-Coliprotec-R-F4-F18-in-Russia-and-CIS-countries.html</id> <title type="text">Prevtec Microbia Receives Market Authorization for Coliprotec(R) F4/F18 in Russia and CIS countries</title> <published>2017-10-24T13:17:53Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/10/24/1324399/0/en/Prevtec-Microbia-Receives-Market-Authorization-for-Coliprotec-R-F4-F18-in-Russia-and-CIS-countries.html" /> <content type="html"><![CDATA[<p><strong>MONTREAL, QUEBEC--(Marketwired - Oct. 24, 2017) -</strong> Prevtec Microbia Inc. ("Prevtec") is pleased to announce that a Market Authorization was received for Russia, including all CIS countries, for its bivalent vaccine Coliprotec® F4/F18, a front line product against post weaning diarrhea (PWD) in pigs caused by <em>E.coli.</em></p>]]></content> <dc:identifier>1324399</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/07/10/1324395/0/fr/Prevtec-Microbia-annonce-qu-Elanco-assure-la-distribution-de-ses-vaccins-Coliprotec-F4-F18-et-Coliprotec-F18-au-Canada.html</id> <title type="text">Prevtec Microbia annonce qu'Elanco assure la distribution de ses vaccins Coliprotec® F4/F18 et Coliprotec® F18 au Canada</title> <published>2017-07-10T16:27:24Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/07/10/1324395/0/fr/Prevtec-Microbia-annonce-qu-Elanco-assure-la-distribution-de-ses-vaccins-Coliprotec-F4-F18-et-Coliprotec-F18-au-Canada.html" /> <content type="html"><![CDATA[<p><strong>MONTRÉAL, QUÉBEC--(Marketwired - 10 juillet 2017) -</strong> Prevtec Microbia (Prevtec) est fière d'annoncer qu'Elanco Santé animale (Elanco) assure la distribution au Canada de ses vaccins destinés aux élevages de porcs, Coliprotec<sup>®</sup> F4/F18 et Coliprotec<sup>®</sup> F18, depuis le 26 juin 2017. Voilà qui complète le portefeuille de vaccins pour porcs contre la bactérie <em>E. coli</em> qu'Elanco offre, elle qui distribuait déjà le Coliprotec<sup>®</sup> F4 au Canada depuis 2013. </p>]]></content> <dc:identifier>1324395</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/07/10/1324392/0/en/Prevtec-Microbia-Announces-Canadian-Distribution-of-Coliprotec-F4-F18-and-Coliprotec-F18-through-Elanco.html</id> <title type="text">Prevtec Microbia Announces Canadian Distribution of Coliprotec® F4/F18 and Coliprotec® F18 through Elanco</title> <published>2017-07-10T16:22:08Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/07/10/1324392/0/en/Prevtec-Microbia-Announces-Canadian-Distribution-of-Coliprotec-F4-F18-and-Coliprotec-F18-through-Elanco.html" /> <content type="html"><![CDATA[<p><strong>MONTREAL, QUEBEC--(Marketwired - July 10, 2017) -</strong> Prevtec Microbia (Prevtec) is pleased to announce that the Company's swine vaccines Coliprotec<sup>®</sup> F4/F18 and Coliprotec<sup>®</sup> F18 will be distributed by Elanco Animal Health (Elanco) starting June 26, 2017. This completes the Coliprotec portfolio of vaccines offered by Elanco against <em>E. coli </em>diseases in pigs, since Coliprotec<sup>®</sup> F4 was already distributed in Canada by Elanco since 2013.</p>]]></content> <dc:identifier>1324392</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/05/23/1324385/0/fr/Coliprotec-R-F4-F18-est-lanc%C3%A9-dans-l-Union-europ%C3%A9enne-par-Elanco-Prevtec-Microbia-livre-un-million-de-doses.html</id> <title type="text">Coliprotec(R) F4/F18 est lancé dans l'Union européenne par Elanco : Prevtec Microbia livre un million de doses</title> <published>2017-05-23T18:26:22Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/05/23/1324385/0/fr/Coliprotec-R-F4-F18-est-lanc%C3%A9-dans-l-Union-europ%C3%A9enne-par-Elanco-Prevtec-Microbia-livre-un-million-de-doses.html" /> <content type="html"><![CDATA[<p><strong>MONTRÉAL, QUÉBEC--(Marketwired - 23 mai 2017) -</strong> Prevtec Microbia Inc. (« Prevtec ») est heureuse d'offrir un compte rendu du lancement commercial de son vaccin bivalent Coliprotec<sup>®</sup> F4/F18 dans l'Union européenne. Coliprotec<sup>®</sup> F4/F18 est un produit phare contre la diarrhée post-sevrage chez les porcs.</p>]]></content> <dc:identifier>1324385</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/05/23/1324380/0/en/Coliprotec-R-F4-F18-is-launched-in-the-EU-through-Elanco-Prevtec-Microbia-delivers-a-million-doses.html</id> <title type="text">Coliprotec(R) F4/F18 is launched in the EU through Elanco: Prevtec Microbia delivers a million doses</title> <published>2017-05-23T18:25:28Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/05/23/1324380/0/en/Coliprotec-R-F4-F18-is-launched-in-the-EU-through-Elanco-Prevtec-Microbia-delivers-a-million-doses.html" /> <content type="html"><![CDATA[<p><strong>MONTREAL, QUEBEC--(Marketwired - May 23, 2017) -</strong> Prevtec Microbia Inc. ("Prevtec") is pleased to provide an update on the commercial launch of its bivalent vaccine Coliprotec® F4/F18 in the European Union, a front line product against post weaning diarrhea (PWD) in pigs.</p>]]></content> <dc:identifier>1324380</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/03/21/1324375/0/fr/Investissement-de-2-5-millions-CAD-dans-Prevtec-Microbia-en-appui-au-lancement-du-second-vaccin-en-Union-Europ%C3%A9enne.html</id> <title type="text">Investissement de 2,5 millions$ CAD dans Prevtec Microbia en appui au lancement du second vaccin en Union Européenne</title> <published>2017-03-21T14:10:21Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/03/21/1324375/0/fr/Investissement-de-2-5-millions-CAD-dans-Prevtec-Microbia-en-appui-au-lancement-du-second-vaccin-en-Union-Europ%C3%A9enne.html" /> <content type="html"><![CDATA[<p><strong>MONTRÉAL, QUÉBEC--(Marketwired - 21 mars 2017) -</strong> Prevtec Microbia a annoncé aujourd'hui une prise de participation de certains des actionnaires de la Société au montant de 2,5 millions de dollars CAD. Les actionnaires Télésystème Ltée, Desjardins-Innovatech, S.E.C., Grupo Corporativo Fuertes, S.L. et Echo Capital FIER Outaouais, Société en commandite ont participé à cette mise de fonds.</p>]]></content> <dc:identifier>1324375</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/03/21/1324370/0/en/Prevtec-Microbia-Receives-Investment-of-CAD-2-5-million-to-support-the-launch-of-its-second-vaccine-in-the-European-Union.html</id> <title type="text">Prevtec Microbia Receives Investment of CAD $2.5 million to support the launch of its second vaccine in the European Union</title> <published>2017-03-21T14:08:28Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/03/21/1324370/0/en/Prevtec-Microbia-Receives-Investment-of-CAD-2-5-million-to-support-the-launch-of-its-second-vaccine-in-the-European-Union.html" /> <content type="html"><![CDATA[<p><strong>MONTREAL, QUEBEC--(Marketwired - March 21, 2017) -</strong> Prevtec Microbia Inc. is pleased to announce that it received an investment from some of the Company's shareholders in the amount of CAD $2.5 million. Telesystem Ltd, Desjardins-Innovatech, S.E.C., Grupo Corporativo Fuertes, S.L. and Echo Capital FIER Outaouais, Limited Partnership participated in this round.</p>]]></content> <dc:identifier>1324370</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/01/12/1324363/0/fr/CORRECTION-Prevtec-Microbia-re%C3%A7oit-l-autorisation-de-mise-en-march%C3%A9-europ%C3%A9en-du-vaccin-vivant-bivalent-Coliprotec-R-F4-F18-contre-E-coli.html</id> <title type="text">CORRECTION - Prevtec Microbia reçoit l'autorisation de mise en marché européen du vaccin vivant bivalent Coliprotec(R) F4/F18 contre E. coli</title> <published>2017-01-12T17:23:11Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/12/1324363/0/fr/CORRECTION-Prevtec-Microbia-re%C3%A7oit-l-autorisation-de-mise-en-march%C3%A9-europ%C3%A9en-du-vaccin-vivant-bivalent-Coliprotec-R-F4-F18-contre-E-coli.html" /> <content type="html"><![CDATA[<p><strong>MONTRÉAL, QUÉBEC--(Marketwired - 12 jan. 2017) -</strong> </p>]]></content> <dc:identifier>1324363</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia inc.;Elanco</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/01/12/1324361/0/en/CORRECTION-Prevtec-Microbia-Receives-European-Marketing-Authorization-for-Coliprotec-R-F4-F18-E-coli-bivalent-live-vaccine.html</id> <title type="text">CORRECTION - Prevtec Microbia Receives European Marketing Authorization for Coliprotec(R) F4/F18 E. coli bivalent live vaccine</title> <published>2017-01-12T17:22:25Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/12/1324361/0/en/CORRECTION-Prevtec-Microbia-Receives-European-Marketing-Authorization-for-Coliprotec-R-F4-F18-E-coli-bivalent-live-vaccine.html" /> <content type="html"><![CDATA[<p><strong>MONTREAL, QUEBEC--(Marketwired - Jan. 12, 2017) -</strong> </p>]]></content> <dc:identifier>1324361</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.;Elanco</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/01/12/1324353/0/en/Prevtec-Microbia-Receives-European-Marketing-Authorization-for-Coliprotec-R-F4-F18-E-coli-bivalent-live-vaccine.html</id> <title type="text">Prevtec Microbia Receives European Marketing Authorization for Coliprotec(R) F4/F18 E. coli bivalent live vaccine</title> <published>2017-01-12T12:00:00Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/12/1324353/0/en/Prevtec-Microbia-Receives-European-Marketing-Authorization-for-Coliprotec-R-F4-F18-E-coli-bivalent-live-vaccine.html" /> <content type="html"><![CDATA[<p><strong>MONTREAL, QUEBEC--(Marketwired - Jan. 12, 2017) -</strong> Prevtec Microbia Inc. is pleased to announce that its German subsidiary, Prevtec Microbia GmbH, received the market authorization from the European Commission for Coliprotec® F4/F18 in the European Union. Coliprotec® F4/F18 is the first single dose oral vaccine intended for active immunization of pigs against enterotoxigenic F4- and F18-positive <em>Escherichia coli</em>, the two most important agents of post-weaning diarrhea (PWD), a major cause of economic loss for swine producers. </p>]]></content> <dc:identifier>1324353</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia Inc.;Elanco</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/01/12/1324357/0/fr/Prevtec-Microbia-re%C3%A7oit-l-autorisation-de-mise-en-march%C3%A9-europ%C3%A9en-du-vaccin-vivant-bivalent-Coliprotec-R-F4-F18-contre-E-coli.html</id> <title type="text">Prevtec Microbia reçoit l'autorisation de mise en marché européen du vaccin vivant bivalent Coliprotec(R) F4/F18 contre E. coli</title> <published>2017-01-12T12:00:00Z</published> <updated>2024-11-24T15:03:45Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/12/1324357/0/fr/Prevtec-Microbia-re%C3%A7oit-l-autorisation-de-mise-en-march%C3%A9-europ%C3%A9en-du-vaccin-vivant-bivalent-Coliprotec-R-F4-F18-contre-E-coli.html" /> <content type="html"><![CDATA[<p><strong>MONTRÉAL, QUÉBEC--(Marketwired - 12 jan. 2017) -</strong> Prevtec Microbia inc. est ravie d'annoncer que sa filiale allemande Prevtec Microbia GmbH vient de recevoir l'autorisation de mise en marché de son vaccin Coliprotec<sup>®</sup> F4/F18 de la Commission Européenne sur le territoire de l'Union européenne. Coliprotec<sup>®</sup> F4/F18 est le premier vaccin oral à dose unique pour l'immunisation active des porcs contre les <em>Escherichia coli</em> entérotoxinogènes F4 et F18 positives, les deux agents les plus importants de la diarrhée post sevrage (DPS), un important facteur de perte économique pour les éleveurs de porcs. </p>]]></content> <dc:identifier>1324357</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prevtec Microbia inc.;Elanco</dc:contributor> <dc:modified>Wed, 31 Jan 2018 05:05 GMT</dc:modified> </entry> </feed>